Pseudopeptide ligands for MHC II-restricted T cells

International Immunology

Volumn 10, Issue 2, 1998, Pages 159-166

  Cotton, Joel ^a   Hervé, Mireille ^a   Pouvelle, Sandra ^a   Maillère, Bernard ^a   Ménez, André ^a  

^a CEA SACLAY   (France)

Author keywords

Amide bond reduction; I E(d); MHC II molecule; N methylation; Pseudopeptides; T cell hybridoma

Indexed keywords

LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PSEUDOPEPTIDE;

ARTICLE; IMMUNOSTIMULATION; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; COBRA VENOMS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HYBRIDOMAS; LIGANDS; LYMPHOCYTE ACTIVATION; METHYLATION; MICE; NEUROTOXINS; OXIDATION-REDUCTION; PEPTIDES; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP; T-LYMPHOCYTES;

EID: 0031908279     PISSN: 09538178     EISSN: None     Source Type: Journal    
DOI: 10.1093/intimm/10.2.159     Document Type: Article

References (49)

1. Ertl, H. C. J. and Xiang, Z. 1996. Novel vaccine approaches. J. Immunol. 156:3579.
2. Boon, T. and Van der Bruggen, P. 1996. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183:725.
3. Smilek, D. E., Wraith, D. C., Hodgkinson, S., Dwivedy, S., Steinman, L. and McDevitt, H. O. 1991. A single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather induce experimental autoimmune encephalomyelitis. Proc. Natl Acad. Sci. USA 88:9633.
4. Samson, M. F. and Smilek, D., E. 1995. Reversal of acute experimental autoimmune encephalomyelitis and prevention of relapses by treatment with a myelin basic protein peptide analogue modified to form long-lived peptide-MHC complexes. J. Immunol. 155:2737.
5. Hoyne, G., Bourne, T., Kristensen, N., Hetzel, C. and Lamb, J. R. 1996. From epitopes to peptidesto immunotherapy. Clin. Immunol. Immunopathol. 80:23.
6. Joost van Neerven, R. J., Ebner, C., Yssel, H., Kapsenberg, M. L. and Lamb, J. R. 1996. T-cell responses to allergens: epitope-specificity and clinical relevance. Immunol. Today 17:526
7. Freeman, G. J., Freedman, A. S., Segil, J. M., Lee, G., Whitman, J. F. and Nadler, L. M. 1989. B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J. Immunol. 143:2714.
8. Freeman, G. J., Gribben, J. G., Boussiotis, V. A., Ng, J. W., Restivo, V. A., Lombard, L. A., Gray, G. S. and Nadler, L. M. 1993. Cloning of B7-2: a CTLA-4 counter receptor that costimulates human T cell proliferation Science 262:909.
9. Schwartz, R. H. 1996. Models of T cell anergy: is there a common molecular mechanism? J. Exp. Med. 184:1.
10. Knight, S. and Stagg, A. J. 1993. Antigen-presenting cell types. Curr. Opin. Immunol. 5:374.
11. Schwartz, R. H. 1990. A cell culture model for T lymphocyte clonal anergy. Science 248:1349.
12. Fuchs, E. J. and Matzinger, P. 1992. B cells turn off virgin but not memory T cells. Science 258: 1156.
13. Milich, D. R., Jones, J. E., McLachlan, A., Houghten, R., Thormton, G. B. and Hughes, J. L. Distinction between immunogenicity and tolerogenicity among HBcAg T cell determinants. J. Immunol. 143:3148.
14. Burstein, H., Shea, C. M. and Abbas, A. K. 1992 Aqueous antigens induce in vivo tolerance selectively in IL-2 and IFN-γ-producing TH1 cells. J. Immunol. 148:3687.
15. Sloan-Lancaster, J., Evavold, B. D. and Allen, P. M. 1993. Induction of T cell energy by altered T-cell- receptor ligand on live antigen-presenting cells. Nature 363:156.
16. Racioppi, L., Ronchese, F., Matis, L. A. and Germain, R. N. 1993. Peptide-major histocompatibility complex class II complexes with mixed agonist/antagonist properties provide evidence for ligand-related differences in T cell receptor-dependent intracellular signaling. J. Exp. Med. 177:1047.
17. Rabinowitz J. D., Beeson C., Wülfing, C., Tate, K., Allen, P. M., Davis, M. M. and McConnell, H. M. 1996. Altered T cell receptor ligands trigger a subset of early T cell signal. Immunity 5:125.
18. Franco, A., Southwood, S., Arrhenius, T., Kuchroo, V. K., Grey, H. M., Sette, A. and Ishioka, G. Y. 1994. T cell receptor antagonist peptides are highly effective inhibitors of experimental allergic encephalomyelitis. Eur. J. Immunol 24:940.
19. Nicholson, L. B., Greer, J. M., Sobel, R. A., Lees, M. B. and Kuchroo, V. K. 1995. An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity 3:397.
20. + T cells. J. Immunol. 157:2160.
21. Powell, M. F., Grey, H., Gaeta, F., Sette, A. and Colon, S. M. 1992. Peptide stability in drug development: a comparison of peptide reactivity in different biological media. J. Pharmac. Sci. 81:731
22. Powell, M. F., Stewart, T., Otvos, L., Urge, L., Grey H., Gaeta, F., Sette, A., Arrhenius, T., Thomson, D., Soda, K. and Colon, S. M. 1993. Peptide stability in drug development. II. Effect of single amino acid substitution and glycosylation on peptide reactivity in human serum. Pharmac. Res. 10,9:731
23. Fauchère, J. L. and Thurieau, C. 1992. Evaluation of the stability of peptides and pseudo-peptides as a tool in peptide drug design. Adv. Drug Res. 23:127.
24. Rodriguez, M., Lignon, M. F., Galas, M. C., Fulcrand, P., Mendre, C., Aumelas, A., Laur, J. and Martinez, J. 1987. Synthesis and biological activities of pseudopeptide analogues of the C-terminal heptapeptide of cholecystokinin. On the importance of the peptide bonds. J. Med. Chem. 30:1366.
25. Lebl, M., Sugg, E. E., Van Binst, G., Van der Elst, P., Tourwe, D., Slaninova, J. and Hruby, V. J. 1987. Analogs of oxytocin containing a modified peptide bond Int. J. Peptide Protein Res. 30:318
26. Alexander, J., Sidney, J., Southwood, S., Ruppert, J., Oseroff, C., Maewal, A., Snoke, K., Serra, M. H., Kubo, R. T., Sette, A. and Grey, H. W. 1994. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1:751.
27. Maillère, B., Mourier, G., Cotton, J., Hervé, M., Leroy, S. and Ménez, A. 1995. Probing immunogenicity by L-Ala and D-amino acids scanning. Mol. Immunol. 32: 1073.
28. Rognan, D., Scapozza, L., Folkers, G. and Daser, A. 1995 Rational design of nonnatural peptides as high affinity ligands for the HLA-B*2705 human leukocyte antigen. Proc. Natl Acad. Sci. USA 92:753.
29. Hill, M. C., Liu, A., Marshall, K. W., Mayer, J., Jorgensen, B., Yuan, B., Cubbon, R. M., Nichols, E. A., Wicker, L. S. and Rothbard, J. B. 1994. Exploration of requirements for peptide binding to HLA DRB1*0101 and DRB1*0401. J. Immunol. 152:2890.
30. Guichard, G., Calbo, S., Muller, S., Kourilsky, P., Briand, J. P. and Abastado, J. P. 1995. Efficient binding of reduced peptide bond pseudopeptides to major histocompatibility complex class I molecule. J. Biol. Chem. 270:26057.
31. Guichard, G., Connan, F., Graff, R., Ostankovitch, M., Muller, S., Guillet, J. G., Choppin, J. and Briand, J. P. 1996. Partially modified retro-inverso pseudopeptides as non-natural ligands for the human class I histocompatibility molecule HLA-A2. J. Med. Chem. 39:2030.
32. Stern, L. J., Brown, J. H., Jardetzky, T. S., Gorga, J. C., Urban, R. G., Strominger, J. L. and Wiley, D. C. 1994. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 368:215.
33. Ghosh, P., Amaya, M., Mellins, E. and Wiley, D. C. 1995. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 378:457.
34. Fremont, D. H., Hendrickson,W. A., Marrack, P. and Kappler, J. 1996. Structures of an MHC class II molecule with covalently bound single peptide. Science 272:1001.
35. O'Sullivan, D., Arrhenius, T., Sidney, J., Del Guercio, M. F., Albertson, M., Wall, M., Oseroff, C., Southwood, S., Colon, S. M., Gaeta, C. A. and Sette, A. 1991. On the interaction of promiscuous antigenic peptides with different DR alleles. J. Immunol. 147:2663.
36. Maillère, B., Mourier, G., Hervé, M. and Ménez, A. 1995. Fine chemical modifications at N- and C-termini enhance peptide presentation to T cells by increasing the lifespan of both free and MHC-complexed peptides. Mol. Immunol. 32:1377
37. Jardetzky, T. S., Gorga, J. C., Busch, R., Rothbard, J., Strominger, J. L. and Wiley, D. C. 1990. Peptide binding to HLA-DR1: a peptide with most residues substituted to alanine retains MHC binding. EMBO J. 9:1797.
38. Marshall, K. W., Liu, A. F., Canales, J., Perahia, B., Jorgensen, B., Gantzos, R. D., Aguilar, B., Devaux, B. and Rothbard, J. B. 1994. Role of polymorphic residues in HLA-DR molecules in allele-specific binding of peptide ligands. J. Immunol. 152:4946.
39. Hervé, M., Maillère, B., Mourier, G., Texier, C., Leroy S. and Ménez, A. 1997. On the immunogenic properties of retro-inverso peptides. Total reversion of T-cell epitopes causes a loss of binding to MHC II molecules Mol. Immunol. 34:157.
40. Fehrentz, J. L. and Castro, B. 1983. An efficient synthesis of optically active α-(t-butoxycarbonylamino)-aldehydes from α-amino acids. Synthesis 676.
41. 2NH peptide bond isostere. Peptides 8:119.
42. Kaljuste, K. and Unden, A. 1993. New method for the synthesis of N-methyl amino acids containing peptides by reductive methylation of amino groups on the solid phase. Int. J. Peptide Res. 42:118.
43. Coste, J., Dufour, M. N., Pantaloni, A. and Castro, B. 1990. Brop: a new reagent for coupling N-methylated amino acids. Tetrahedron Lett. 31:669.
44. Beeson, C. and McConnell, H. M. 1994. Kinetic intermediates in the reactions between peptides and proteins of major histocompatibility complex class II. Proc. Natl Acad. Sci. USA 91:8842.
45. Maillère, B., Cotton J., Mourier, G., Léonetti, M., Leroy, S. and Ménez, A. 1993. Role of thiols in the presentation of a snake toxin to murine T cells. J. Immunol. 150: 5270.
46. d molecules J. Immunol. 143:3289.
47. Bogen, B. and Lambris, J. D. 1989. Minimum length of an idiotypic peptide and a model for its binding to a major histocompatibility complex class II molecule. EMBO J. 8:1947,
48. Schild, H., Grüneberg, U., Pougialis, G., Wallny, H. J., Keilholz, W., Stefanovic, S. and Rammensee, H. G. 1995. Natural ligand motifs of H-2E molecules are allele specific and illustrate homology to HLA-DR molecules. Int. Immunol. 7:1957.
49. Marraud, M., Dupont, V., Grand, V., Zerkout, S., Lecoq, A., Boussard, G., Vidal, J., Collet, A. and Aubry, A. 1993. Modifications of the amide bond and conformational constraints in pseudopeptide analogues. Biopolymers 33:1135.